Amgen gets European rec for Vectibix uses; Pfizer to sell Irish plant to BioMarin;

@FiercePharma: High court rules against Vermont in data-mining case. Report | Follow @FiercePharma

> Amgen said Europe's Committee for Medicinal Products for Human Use has endorsed additional indications for its cancer treatment Vectibix in patients with advanced colorectal cancer. Report

> BioMarin will buy Pfizer's biologics manufacturing plant in Shanbally, Ireland to add production capacity for its candidate mucopolysaccharidosis treatment. Report

> Shares of Acura Pharmaceuticals climbed after regulators delayed approval of a potential competitor to its pain drug Oxecta. Report

> West Virginia judges must revisit decisions allowing lawsuits against drug maker Mylan over its fentanyl pain patch to remain in the state. Report

> Brazilian pharmaceutical retailer Brazil Pharma raised 414 million Brazilian reais ($260.3 million) through its IPO on the Brazilian Stock Exchange. Report

Biotech News

  @FierceBiotech: FDA shoots down Pfizer, Pain Therapeutics drug. Story | Follow @FierceBiotech

> As Ph3 failures spike Big Pharma hits the brakes on R&D spending. Report

> Genentech leaves the numbers blank in Forma deal. News

> Bristol-Myers' pioneering diabetes drug bests rivals in 2-year study. Item 

> Icagen shares rocket up on news of Pfizer buyout talks. Article 

Biotech IT News

> Gaming, simulation combine to treat PTSD in soldiers. Story

> Cmed names ePRO vet Rotherman to board. Report

> Shire, Mediciglobal hear big bang of social media in e-recruitment. Article

> Virtify, in hosting deal, flies structured-content flag despite EU snub. News

> Safe-Biopharma teams with Verizon, furthers NCI work. Report

> Pfizer's virtual trial: Open-source meets old pharma. Article

Medical Device News

> BioMerieux unveils quicker salmonella test. Report

> Smith & Nephew buys TENET Medical Engineering. Item

> Porton calls 3M suit 'false and reckless.' Story

> St. Jude device eases migraines, but can it convince the FDA? Article

> J&J opens Chinese innovation center. News

And Finally... The British Medical Journal urged David Cameron's government to abandon its legislation overhauling the National Health Service, "sweep the bill's mangled remains into an unmarked grave and move on." Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.